ENHERTU - Discover a new indication & how it may help certain patients with unmet needs ~ March 4th

Indication

ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.

REGISTER NOW!

PP-US-ENG-0309_DSI Enhertu Live Broadcas

.

Download • 383KB